| Document |
Document Title |
|
WO/2023/288324A1 |
Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK‑274 or aficamten) and may include tit...
|
|
WO/2023/287750A1 |
This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or tro...
|
|
WO/2023/284134A1 |
Disclosed in the present invention are a cell nucleus-targeting upconversion fluorescent probe, and a preparation method therefor and the use thereof. The fluorescent probe is of a shell-core structure, wherein the core of the fluorescen...
|
|
WO/2023/284660A1 |
A scar diagnosis reagent and the use thereof, which use comprises the use of a detection reagent of a CD3 +CD8 + cytotoxic T cell, NKG2A, KLRC1, or soluble human leukocyte antigen-E (sHLA-E) in the preparation of a reagent or kit for kel...
|
|
WO/2023/285405A1 |
The present invention relates to new and improved methods for the use of Compound 1 in the treatment of inflammatory diseases and/or diseases associated with hypersecretion of IFNa and/or interferons ("interferonopathies", especially typ...
|
|
WO/2023/280150A1 |
A pharmaceutical composition comprising: a form of compound of formula (I) and at least one additional therapeutic agent, and optionally one or more pharmaceutically acceptable carriers.
|
|
WO/2023/283062A1 |
Provided herein is a 6β-naltrexol formulation at dosages sufficient for the treatment of a condition involving upregulated basal signaling of the μ-opioid receptor (MOR) system.
|
|
WO/2023/280283A1 |
The present invention relates to a compound used as an SHP2 inhibitor and the use thereof. Specifically, the compound of the present invention has a structure as represented by formula I', wherein the definitions of each group and each s...
|
|
WO/2023/282296A1 |
The present invention provides: a pH-responsive lipid derivative represented by the structure shown in a formula (i) (where each symbol in the formula is as defined in the description); and a pH-responsive carrier that is useful as a car...
|
|
WO/2023/281007A1 |
The present invention relates to a particularly advantageous new therapeutic use of melflufen (melphalan flufenamide; L-melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof: in the treatment or prophylaxis of multiple mye...
|
|
WO/2023/281026A1 |
The invention relates to transduction buffers and methods for transducing molecules into cells using said buffers. The invention also relates to pharmaceutical compositions comprising said transduction buffers and methods of treatment in...
|
|
WO/2023/282544A1 |
The objective of the present invention is to provide a composition for cancer alleviation, prevention, or treatment, comprising a CDK4/6 inhibitor and a tricyclic antidepressant as active ingredients. If a composition comprising a CDK4/6...
|
|
WO/2023/283329A1 |
The present disclosure provides methods of treating a disease, disorder, or condition associated with ER+/HER2+ cancer using Compound 1, or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/282145A1 |
Provided is a composition for preventing or treating tissue aging which contains an S-adenosylmethionine synthase inhibitor. Also provided is a method for screening an anti-aging substance, the method comprising (1) a step for culturing ...
|
|
WO/2023/282269A1 |
Disclosed is a prophylactic or therapeutic drug for Parkinson's disease, which comprises a trisulfide compound and is characterized by being administered in combination with a drug that is used for a dopamine supplementation therapy.
|
|
WO/2023/283108A1 |
Compositions promote restful sleep and/or to a feeling of restful sleep. Specifically, the compositions of the present invention comprise a combination of hops extract, magnolia bark extract, melatonin, magnesium, rhodiola extract, L-the...
|
|
WO/2023/282675A1 |
The present invention relates to a combination use of a novel Lactobacillus plantarum IMB19 strain and/or polysaccharides derived from the strain with an anticancer drug for preventing or treating tumors. The novel Lactobacillus plantaru...
|
|
WO/2023/280767A1 |
A sanggenon preparation comprising a sanggenon content of at least 5% (w/w), for use in the prophylactic or therapeutic anti-β-coronavirus treatment of a subject in need of anti-β-coronavirus treatment.
|
|
WO/2023/279893A1 |
A microneedle made of a strongly hydrophilic substrate. A composition of polyvinyl alcohol and a small molecule polyhydroxy compound is used as a substrate to prepare a microneedle having a strongly hydrophilic surface and a drug-loaded ...
|
|
WO/2023/280152A1 |
A pharmaceutical composition comprising: a compound of formula (I) formulated for storage at room temperature and at least one additional therapeutic agent.
|
|
WO/2023/281097A1 |
The present invention provides methods comprising one or compounds according to Formula (I) alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g. prostate canc...
|
|
WO/2023/277502A1 |
The present invention relates to a method for prevention, alleviation, or treatment of cancer patients, especially epithelial mesenchymal transition (EMP)-subtype cancer patients. If PHGDH, SHMT and MTHFD2 inhibitors are co-administered ...
|
|
WO/2023/278597A1 |
In general, the invention relates to pharmaceutical compositions comprising a 5-HT2C agonist, and methods of treating conditions associated with central hypoventilation including administering a 5-HT2C agonist.
|
|
WO/2022/040771A9 |
The invention describes a method for preparing bone grafts from a preparation of a Biosilicate® in (110), in (120) infiltrating barbotine Biosilicate® into the Biosilicate® from (110), in (130) burning the infiltrated Biosilicate® fr...
|
|
WO/2022/246459A9 |
Provided herein is a a combination, comprising: (i) one or more YAP/TAZ-TEAD inhibitors; and (ii) one or more KRAS inhibitors, such as the specific YAP/TAZ-TEAD inhibitors and KRAS inhibitors described herein. Also provided herein are me...
|
|
WO/2023/278876A1 |
Provided is a pharmaceutical composition that may be suitable for topical application. The pharmaceutical composition for topical application includes dimethylcurcumin and/or a salt thereof as an active pharmaceutical ingredient in a ran...
|
|
WO/2023/273364A1 |
A new type polyethylene glycol lipid and the use thereof. The lipid is free of in-vivo cleavable bonds, and can deliver a bioactive substance to a target cell or organ more stably. In addition, the new type polyethylene glycol lipid can ...
|
|
WO/2023/276768A1 |
Provided are: a novel marker useful for measuring hypoxia or predicting the exacerbation of pathoses related to hypoxia; a hypoxia measurement method and a pathosis exacerbation prediction method which use said marker as an indicator; a ...
|
|
WO/2023/278364A1 |
A method for inducing synaptogenesis in a subject having a neurodegenerative disease, the method comprising administering an angiotensin or analogue thereof in a therapeutically effective amount to induce synaptogenesis in said subject. ...
|
|
WO/2023/276869A1 |
The present disclosure includes: a biomarker for predicting the prognosis of a subject having cancer containing IGFBP-1 after a treatment of the subject with an angiogenesis inhibitor; a method for predicting the prognosis of a subject h...
|
|
WO/2023/277130A1 |
Provided are a novel biomarker that can simply detect a tubulointerstitial disorder or grasp a disease state of a kidney disease using a urine specimen and use thereof. This biomarker is sCD14-ST in urine.
|
|
WO/2023/273422A1 |
The present invention provides a focal adhesion kinase splicing isomer and an application thereof, specifically provides an application of a reagent for detecting a focal adhesion kinase splicing isomer in preparing a diagnostic agent fo...
|
|
WO/2023/275173A1 |
The present disclosure is directed to the use of a compound of Formula (III) in the treatment of DLBCL.
|
|
WO/2023/277620A1 |
The present invention relates to use of a combination comprising: a peptide or a conjugate thereof, having activity on all of glucagon, GLP-1 and GIP receptor; and a SGLT-2 inhibitor.
|
|
WO/2023/272794A1 |
A combined pharmaceutical composition for preventing cardiovascular diseases complicated by hypertension, comprising a homocysteine reducing drug and a platelet reducing drug. The homocysteine reducing drug is folic acid, and the platele...
|
|
WO/2023/274095A1 |
An application of a kaurane compound in the preparation of a drug for treating inflammatory bowel disease. The kaurane compound can mitigate the inflammatory reaction of dextran sodium sulfate (DSS)-induced inflammatory bowel disease mod...
|
|
WO/2023/278497A1 |
The invention disclosed herein relates to novel methods, and compositions, for preventing, inhibiting, reducing, and/or shortening the duration of symptoms associated with the consumption of alcohol and/or hangover symptoms associated wi...
|
|
WO/2023/275622A2 |
The invention generally relates to methods and systems for controlling electrolyte excretion, e.g., sodium, potassium, chloride and bicarbonate, which is useful to remove body fluid during sweating.
|
|
WO/2023/275249A1 |
The present invention relates to anethole trithione (ATT) for use for preventing, treating, and/or lessening the severity or progression of, a vasculitis in a subject in need thereof, in particular of Kawasaki and Kawasaki-like disease.
|
|
WO/2023/278987A1 |
Provided herein are methods for the add-on treatment of schizophrenia using a vesicular monoamine transporter isoform 2 (VMAT2) inhibitor. In certain embodiments, the VMAT2 inhibitor is valbenazine or a pharmaceutically acceptable salt t...
|
|
WO/2023/276942A1 |
Disclosed is a pharmaceutical agent that inhibits expression of VEGFA in fibroblasts. This pharmaceutical agent can inhibit increase in expression of VEGFA in fibroblasts caused by infrared rays, heat, etc.
|
|
WO/2023/274418A1 |
A novel proteolysis-targeting chimeric compound, and an application thereof in the preparation of a drug for treating related diseases. A compound represented by formula (I) and a pharmaceutically-acceptable salt thereof are specifically...
|
|
WO/2023/277610A1 |
The present invention relates to: a pharmaceutical composition which, by loading a nucleic acid-based drug in cell-derived natural or artificial nanovesicles, is capable of introducing the nucleic acid-based drug into cells; and a method...
|
|
WO/2023/276866A1 |
The present invention pertains to a therapeutic composition for Barrett's esophagus and addresses the problem of providing a therapeutic composition for restoring Barrett's esophagus to normal esophagus and a method for treating Barrett'...
|
|
WO/2023/272607A1 |
A diagnosis and treatment integrated apoptotic body and a preparation method therefor. The preparation method comprises: culturing cells in a culture medium containing an antitumor drug and a nano contrast agent to obtain a culture mediu...
|
|
WO/2022/271861A1 |
The invention generally relates to pharmaceuticals and therapeutic methods. More particularly, the invention provides small molecule EGFR inhibitors (e.g., EGFR tyrosine kinase inhibitor compounds) and pharmaceutical compositions thereof...
|
|
WO/2022/269266A1 |
A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre...
|
|
WO/2022/269265A1 |
A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 3, for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabol...
|
|
WO/2022/270071A1 |
The present invention provides: an agent for preventing liver fibrosis, which comprises at least one nucleic acid selected from the group consisting of a nucleic acid that comprises a nucleotide sequence comprising a seed sequence for mi...
|
|
WO/2022/269267A1 |
A pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, for use in the treatment of an autoimmune disease within a subjec...
|
